Evidence map›Paper›PMID 40277970›Full record

ArticleMembranes2025

Hybrid Adsorption-Microfiltration Process for the Pretreatment of Sulfide-Containing Seawater: A Promising Strategy to Mitigate Membrane Fouling.

Ludi Song, Chengyi Dai, Zifei Chai, Mengzhe Cai, Huazhang Li, Sifan Wu, Lin Zhang, Yaqin Wu, Haitao Zhu

Abstract read
In one paragraph

Article in Membranes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ludi SongCollege of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310058, China.
Chengyi DaiHangzhou Water Treatment Technology Development Center Co., Ltd., Hangzhou 310012, China.
Zifei ChaiHangzhou Water Treatment Technology Development Center Co., Ltd., Hangzhou 310012, China.
Mengzhe CaiHangzhou Water Treatment Technology Development Center Co., Ltd., Hangzhou 310012, China.
Huazhang LiHangzhou Water Treatment Technology Development Center Co., Ltd., Hangzhou 310012, China.
Sifan WuHangzhou Water Treatment Technology Development Center Co., Ltd., Hangzhou 310012, China.
Lin ZhangCollege of Chemical and Biological Engineering, Zhejiang University, Hangzhou 310058, China.
Yaqin WuHangzhou Water Treatment Technology Development Center Co., Ltd., Hangzhou 310012, China.
Haitao ZhuHangzhou Water Treatment Technology Development Center Co., Ltd., Hangzhou 310012, China.ORCID 0000-0003-4824-5261

Funding

Key Research Program of Hangzhou 2023SZD0140
6 · The paper itself

Abstract

The presence of dissolved sulfides in feed seawater causes severe elemental sulfur fouling in the reverse osmosis (RO) process. However, current pretreatment methods suffer from large footprint, high energy consumption, and limitations in effluent quality. In this study, adsorption and microfiltration are merged into a single process for the pretreatment of sulfide-containing seawater. Powdered activated carbon (PAC) was selected for its superior adsorption capacity (14.6-fold) and faster kinetics (3.9-fold) for sulfide removal compared to granular activated carbon. The high surface area and multiple pore structures of PAC facilitate surface and intraparticle diffusion, as well as anion-π conjugation likely occur between PAC and sulfide. Polypropylene microporous membranes, capable of tolerating high PAC dosages, were used in the hybrid process. Long-term pilot tests demonstrated that the effluent (turbidity < 1 NTU and SDI

Indexed as

hybrid processmembrane fouling mitigationmicrofiltrationpowdered activated carbonsulfide-containing seawater desalination

Identifiers

PMID40277970
PMCPMC12029300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.